Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC

Phase 3 EVOKE-03/KEYNOTE-D46 failed both primary endpoints for sacituzumab govitecan plus pembrolizumab in first-line PD-L1-high metastatic NSCLC: PFS was 11.8 vs 7.7 months (HR 0.81; P=0.0252) but missed the prespecified significance threshold, while interim OS was 21.5 vs 22.8 months (HR 1.07; P=0.7155). The combination improved objective response rate to 55.6% from 43.7%, but substantially increased grade 3+ treatment-related adverse events to 55.7% from 16.5%. The lack of statistically significant PFS or OS benefit is a material setback for the regimen's first-line lung-cancer development prospects.

Analysis

The commercial implication is larger than the immediate trial headline for Gilead: without a registrationally compelling survival signal, sacituzumab is unlikely to displace pembrolizumab monotherapy in the highest-value first-line PD-L1-high lung segment. That removes a potential multi-billion-dollar label-expansion narrative and leaves Trodelvy more dependent on increasingly competitive breast-cancer indications. The unfavorable efficacy-to-toxicity tradeoff also raises the hurdle for payer adoption and for any attempt to pursue a narrower biomarker-defined lung population.

Merck is the relative beneficiary because the result reinforces the durability of its monotherapy standard of care and reduces near-term combination-driven share loss. The more important second-order read-through is for the TROP2 ADC field: AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan and other TROP2 programs may face greater investor scrutiny on whether response-rate improvements can translate into survival without unacceptable discontinuations. This is not a class-wide failure—payload, dosing, and patient selection differ materially—but it lowers the valuation premium assigned to unproven frontline ADC combinations until cleaner randomized data emerge.

Near term, GILD may underperform biotech indices as sell-side models remove probability-weighted NSCLC revenue and reassess Trodelvy peak-sales assumptions; the move should be restrained by Gilead's diversified HIV and oncology cash flows. Over 1-3 months, the key catalyst is management's updated development strategy, including whether it continues to fund broad lung-cancer studies or pivots to biomarker-enriched cohorts. The thesis is falsified if mature survival follow-up materially improves, a predefined subgroup shows a reproducible benefit, or Gilead identifies a development path with a credible regulatory endpoint and lower treatment burden.

Key Decisions for Investors

• Initiate a small 1-3 month long MRK / short GILD pair, sized at roughly equal beta: MRK retains competitive protection in first-line PD-L1-high NSCLC while GILD faces a probability-weighted Trodelvy label-expansion reset. Use a 5-7% adverse move in the relative spread as a risk limit; cover the GILD leg if management provides a convincing biomarker-led registrational path.
• Reduce or avoid adding to GILD on this read-through until the next pipeline update quantifies any revision to Trodelvy lung-development spend and peak-sales expectations. The expected downside is likely modest at the corporate level given diversification, making this a relative-value trade rather than a high-conviction outright short.
• Place an alert on AZN and Daiichi Sankyo (4568 JP): weakness driven solely by broad TROP2-ADC extrapolation could create an entry opportunity, but do not short the names on this result alone. Require evidence of efficacy/safety deterioration in their own randomized frontline datasets before treating this as a class-level thesis.
• Watch for reimbursement or guideline commentary over the next 3-6 months; absence of a survival benefit combined with materially higher treatment burden should prevent meaningful off-label uptake, supporting further downward revisions to GILD's NSCLC revenue optionality.